Hep c treatment new drugs

There have been significant advancements in the treatment of Hepatitis C (HCV) in recent years, with the development of new direct-acting antiviral (DAA) medications. These new drugs have revolutionized the treatment of HCV, offering high cure rates, fewer side effects, and shorter treatment durations. Here are some of the new HCV treatment options:

1. Epclusa (sofosbuvir/velpatasvir): A single tablet regimen that combines sofosbuvir and velpatasvir, approved in 2016 for treatment-naive and treatment-experienced patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection.
2. Harvoni (ledipasvir/sofosbuvir): A single tablet regimen that combines ledipasvir and sofosbuvir, approved in 2014 for treatment-naive patients with genotype 1 HCV infection.
3. Vosevi (sofosbuvir/velpatasvir/voxilaprevir): A single tablet regimen that combines sofosbuvir, velpatasvir, and voxilaprevir, approved in 2017 for treatment-experienced patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection.
4. Mavyret (glecaprevir/pibrentasvir): A single tablet regimen that combines glecaprevir and pibrentasvir, approved in 2017 for treatment-naive and treatment-experienced patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection.
5. Zepatier (elbasvir/grazoprevir): A single tablet regimen that combines elbasvir and grazoprevir, approved in 2016 for treatment-naive patients with genotype 1 or 4 HCV infection.
6. Olysio (simeprevir): A protease inhibitor approved in 2013 for treatment-experienced patients with genotype 1 HCV infection.
7. Technivie (ombitasvir/paritaprevir/ritonavir): A fixed-dose combination of ombitasvir, paritaprevir, and ritonavir, approved in 2014 for treatment-experienced patients with genotype 1 HCV infection.
8. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir): A fixed-dose combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir, approved in 2014 for treatment-naive patients with genotype 1 HCV infection.

These new medications have significantly improved treatment outcomes for HCV patients, with cure rates often exceeding 90%. They have also reduced the need for interferon-based therapies, which were associated with significant side effects and limited treatment options.

It's essential to note that the choice of treatment depends on various factors, including the patient's genotype, treatment history, and medical history. Patients should consult with their healthcare provider to determine the best treatment option for their individual needs.